Peter Goettel

Berlin Heals GmbH is a life science company that was founded in 2014 with the mission to develop its proprietary c-mic technology to treat heart failure. The company is based in Berlin, Germany, and has subsidiaries in Switzerland. The German company has developed a novel implantable electroceutical device called "c-mic," which is a small implantable device that propagates reverse remodeling of the cardiac muscle tissue. The c-mic device is a breakthrough near-curative treatment for patients with systematic and refractory heart failure. The company intends to test the efficacy of its technology with patients suffering from heart failure with preserved ejection fractions (HFPEF-patients). The CEOs of the company are Peter Goettel and Johannes Müller.

Berlin Cures GmbH engages in the development and production of a drug for the treatment of chronic heart failure. The company was founded on September 9, 2014 and is headquartered in Berlin, Germany.

Part of Berlin Cures GmbH, Cures Holding AG is a Swiss joint stock company based in Zug, Switzerland. Cures Holding AG specializes in developing a neutralizer for pathogenic functional autoantibodies. The company is home to an unrivaled platform-technology established around BC 007. The company was founded in 2014 by Johannes Müller, and Oliver von Stein has been the CEO of the company since 2023.

Berlin Cures GmbH engages in the development and production of a drug for the treatment of chronic heart failure. The company was founded on September 9, 2014 and is headquartered in Berlin, Germany.

Part of Berlin Cures GmbH, Cures Holding AG is a Swiss joint stock company based in Zug, Switzerland. Cures Holding AG specializes in developing a neutralizer for pathogenic functional autoantibodies. The company is home to an unrivaled platform-technology established around BC 007. The company was founded in 2014 by Johannes Müller, and Oliver von Stein has been the CEO of the company since 2023.

Part of Berlin Cures GmbH, Cures Holding AG is a Swiss joint stock company based in Zug, Switzerland. Cures Holding AG specializes in developing a neutralizer for pathogenic functional autoantibodies. The company is home to an unrivaled platform-technology established around BC 007. The company was founded in 2014 by Johannes Müller, and Oliver von Stein has been the CEO of the company since 2023.

Part of Berlin Cures GmbH, Cures Holding AG is a Swiss joint stock company based in Zug, Switzerland. Cures Holding AG specializes in developing a neutralizer for pathogenic functional autoantibodies. The company is home to an unrivaled platform-technology established around BC 007. The company was founded in 2014 by Johannes Müller, and Oliver von Stein has been the CEO of the company since 2023.